# QUIREDEX (NCT00480363)

> QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00480363
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: PETHEMA Foundation
- Conditions: Multiple Myeloma
- Interventions: Maintenance with lower doses of lenalidomide and dexamethasone
- Enrollment: 120
- Primary outcome: The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- YouTube: 6
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=quiredex-nct00480363

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00480363", "email": "<work email>"}; the inbox owner confirms by the emailed link.